Search

Your search keyword '"Panicali, Dennis L."' showing total 22 results
Start Over Author "Panicali, Dennis L."
22 results on '"Panicali, Dennis L."'

3. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

Author

Robinson, Harriet L., Montefiori, David C., Johnson, R. Paul, Manson, Kelledy H., Kalish, Marcia L., Lifson, Jeffrey D., Rizvi, Tahir A., Lu, Shan, Hu, Shiu-Lok, Mazzara, Gail P., Panicali, Dennis L., Herndon, James G., Glickman, Rhona, Candido, Maria A., Lydy, Shari L., Wyand, Michael S., and McClure, Harold M.

Published
1999
Full Text
View/download PDF

7. Recombinant Fowlpox Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma

Author

Rosenberg, Steven A., Yang, James C., Schwartzentruber, Douglas J., Hwu, Patrick, Topalian, Suzanne L., Sherry, Richard M., Restifo, Nicholas P., Wunderlich, John R., Seipp, Claudia A., Rogers-Freezer, Linda, Morton, Kathleen E., Mavroukakis, Sharon A., Gritz, Linda, Panicali, Dennis L., and White, Donald E.

Subjects
Adult, Male, Vaccines, Fowlpox virus, Membrane Glycoproteins, HLA-A Antigens, Vaccinia virus, CD8-Positive T-Lymphocytes, Middle Aged, Cancer Vaccines, Article, Neoplasm Proteins, Epitopes, Interferon-gamma, Antigens, Neoplasm, Cell Line, Tumor, Immunoglobulin G, HLA-A2 Antigen, Humans, Interleukin-2, Female, Peptides, Melanoma, Aged, gp100 Melanoma Antigen
Abstract

The purpose of this study was to evaluate the immunological responses and therapeutic effectiveness of immunization with fowlpox vaccines encoding the gp100 melanoma antigen in patients with metastatic melanoma.In three consecutive clinical trials, patients were immunized with recombinant fowlpox viruses encoding three different forms of the melanoma/melanocyte-associated antigen gp100: (a) the native, full-length gp100 molecule; (b) the gp100 molecule with two amino acids modified to increase binding to HLA-A*0201 molecules; and (c) a "minigene" construct encoding a single, modified epitope gp100:209-217(210M) targeted to the endoplasmic reticulum. The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma.Reactivity against gp100 was not seen in any patient before receiving fowlpox immunization. Whereas just one of seven patients developed reactivity after receiving fowlpox encoding native gp100, 10 of 14 patients who received fowlpox encoding the anchor modified full-length gp100 exhibited reactivity against the native gp100 molecule, and 12 of 16 patients were successfully immunized after inoculation with the modified minigene construct (p2 = 0.02). There was no difference in the latter group between those randomized to vaccination by i.v. or i.m. routes. There was one partial cancer regression in the group of 46 patients receiving virus in the absence of interleukin (IL)-2. Once patients showed evidence of progressive disease, they were eligible for "cross-over" treatment to IL-2 alone or with the fowlpox virus. None of the 13 patients receiving the full-length or modified full-length forms of gp100 responded when receiving IL-2, whereas 6 of 12 patients who received the fowlpox containing the minigene construct and then received IL-2 showed objective cancer regressions, including three patients with complete regression.These data underscore the importance of modifying anchor residues of nonmutated self-antigen peptides to generate cellular immune responses after immunization and support the further investigation of recombinant fowlpox viruses encoding modified epitopes administered in combination with IL-2.

Published
2003

8. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Author

Kantoff, Philip W., primary, Schuetz, Thomas J., additional, Blumenstein, Brent A., additional, Glode, L. Michael, additional, Bilhartz, David L., additional, Wyand, Michael, additional, Manson, Kelledy, additional, Panicali, Dennis L., additional, Laus, Reiner, additional, Schlom, Jeffrey, additional, Dahut, William L., additional, Arlen, Philip M., additional, Gulley, James L., additional, and Godfrey, Wayne R., additional

Published
2010
Full Text
View/download PDF

9. Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

Author

Lindsey, Kimberly R., primary, Gritz, Linda, additional, Sherry, Richard, additional, Abati, Andrea, additional, Fetsch, Patricia A., additional, Goldfeder, Lisa C., additional, Gonzales, Monica I., additional, Zinnack, Kimberly A., additional, Rogers-Freezer, Linda, additional, Haworth, Leah, additional, Mavroukakis, Sharon A., additional, White, Donald E., additional, Steinberg, Seth M., additional, Restifo, Nicholas P., additional, Panicali, Dennis L., additional, Rosenberg, Steven A., additional, and Topalian, Suzanne L., additional

Published
2006
Full Text
View/download PDF

10. Role of Genes That Modulate Host Immune Responses in the Immunogenicity and Pathogenicity of Vaccinia Virus

Author

Jackson, Shawn S., primary, Ilyinskii, Petr, additional, Philippon, Valérie, additional, Gritz, Linda, additional, Yafal, Alicia Gómez, additional, Zinnack, Kimberly, additional, Beaudry, Kristin R., additional, Manson, Kelledy H., additional, Lifton, Michelle A., additional, Kuroda, Marcelo J., additional, Letvin, Norman L., additional, Mazzara, Gail P., additional, and Panicali, Dennis L., additional

Published
2005
Full Text
View/download PDF

11. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity

Author

Barouch, Dan H., primary, Pau, Maria G., additional, Custers, Jerome H. H. V., additional, Koudstaal, Wouter, additional, Kostense, Stefan, additional, Havenga, Menzo J. E., additional, Truitt, Diana M., additional, Sumida, Shawn M., additional, Kishko, Michael G., additional, Arthur, Janelle C., additional, Korioth-Schmitz, Birgit, additional, Newberg, Michael H., additional, Gorgone, Darci A., additional, Lifton, Michelle A., additional, Panicali, Dennis L., additional, Nabel, Gary J., additional, Letvin, Norman L., additional, and Goudsmit, Jaap, additional

Published
2004
Full Text
View/download PDF

12. Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL

Author

Chen, Ji-Li, primary, Dunbar, P. Rod, additional, Gileadi, Uzi, additional, Jäger, Elke, additional, Gnjatic, Sacha, additional, Nagata, Yasuhiro, additional, Stockert, Elisabeth, additional, Panicali, Dennis L., additional, Chen, Yao-Tseng, additional, Knuth, Alexander, additional, Old, Lloyd J., additional, and Cerundolo, Vincenzo, additional

Published
2000
Full Text
View/download PDF

21. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

Author

Keefer, Michael C., Frey, Sharon E., Elizaga, Marnie, Metch, Barbara, De Rosa, Stephen C., Barroso, Paulo F., Tomaras, Georgia, Cardinali, Massimo, Goepfert, Paul, Kalichman, Artur, Philippon, Valérie, McElrath, M. Juliana, Jin, Xia, Ferrari, Guido, Defawe, Olivier D., Mazzara, Gail P., Montefiori, David, Pensiero, Michael, Panicali, Dennis L., and Corey, Lawrence

Subjects
*AIDS vaccines, *CLINICAL trials, *FOWL pox, *IMMUNOGLOBULINS, *VACCINIA, *T cells, *VIRAL envelopes, *INTERFERONS
Abstract

Abstract: We evaluated replication-defective poxvirus vectors (modified vaccinia Ankara [MVA] and fowlpox [FPV]) in a homologous and heterologous vector prime-boost vaccination regimen containing matching HIV inserts (MVA-HIV and FPV-HIV) given at months 0, 1, 3, 5 and 7 in 150 healthy HIV-negative vaccinia-naïve participants. FPV-HIV alone was poorly immunogenic, while the high dose (109 pfu/2ml) of MVA-HIV alone elicited maximal responses after two injections: CD4+ and CD8+ T-cell responses in 26/55 (47.3%) and 5/60 (8.3%) of participants, respectively, and IFN-γ ELISpot responses in 28/62 (45.2%). The infrequent CD8+ T-cell responses following MVA-HIV priming were boosted only by the heterologous (FPV-HIV) construct in 14/27 (51.9%) of participants post 4th vaccination. Alternatively, HIV envelope-specific binding antibodies were demonstrated in approximately two-thirds of recipients of the homologous boosting regimen, but in less than 20% of subjects after the heterologous vector boost. Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

22. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Author

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, and White DE

Subjects
Adult, Aged, Antigens, Neoplasm chemistry, CD8-Positive T-Lymphocytes metabolism, Cancer Vaccines, Cell Line, Tumor, Epitopes chemistry, Female, HLA-A Antigens genetics, HLA-A2 Antigen, Humans, Immunoglobulin G chemistry, Interferon-gamma metabolism, Interleukin-2 metabolism, Male, Membrane Glycoproteins metabolism, Middle Aged, Neoplasm Proteins metabolism, Peptides chemistry, Vaccines chemistry, Vaccinia virus metabolism, gp100 Melanoma Antigen, Fowlpox virus chemistry, Melanoma metabolism, Membrane Glycoproteins chemistry, Neoplasm Proteins chemistry
Abstract

Purpose: The purpose of this study was to evaluate the immunological responses and therapeutic effectiveness of immunization with fowlpox vaccines encoding the gp100 melanoma antigen in patients with metastatic melanoma., Experimental Design: In three consecutive clinical trials, patients were immunized with recombinant fowlpox viruses encoding three different forms of the melanoma/melanocyte-associated antigen gp100: (a) the native, full-length gp100 molecule; (b) the gp100 molecule with two amino acids modified to increase binding to HLA-A*0201 molecules; and (c) a "minigene" construct encoding a single, modified epitope gp100:209-217(210M) targeted to the endoplasmic reticulum. The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma., Results: Reactivity against gp100 was not seen in any patient before receiving fowlpox immunization. Whereas just one of seven patients developed reactivity after receiving fowlpox encoding native gp100, 10 of 14 patients who received fowlpox encoding the anchor modified full-length gp100 exhibited reactivity against the native gp100 molecule, and 12 of 16 patients were successfully immunized after inoculation with the modified minigene construct (p2 = 0.02). There was no difference in the latter group between those randomized to vaccination by i.v. or i.m. routes. There was one partial cancer regression in the group of 46 patients receiving virus in the absence of interleukin (IL)-2. Once patients showed evidence of progressive disease, they were eligible for "cross-over" treatment to IL-2 alone or with the fowlpox virus. None of the 13 patients receiving the full-length or modified full-length forms of gp100 responded when receiving IL-2, whereas 6 of 12 patients who received the fowlpox containing the minigene construct and then received IL-2 showed objective cancer regressions, including three patients with complete regression., Conclusions: These data underscore the importance of modifying anchor residues of nonmutated self-antigen peptides to generate cellular immune responses after immunization and support the further investigation of recombinant fowlpox viruses encoding modified epitopes administered in combination with IL-2.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results